← All trials
NCT06081803
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Oct 13, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sejong General HospitalLead sponsor
- Chonnam National UniversityCollaborator
- Daegu Catholic UniversityCollaborator
- Inje UniversityCollaborator
- Ilsan HospitalCollaborator
- Sungkyunkwan UniversityCollaborator
- Sejong General HospitalReponsible party - principal investigator
- Sejong General HospitalSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.